Biotechnology company Lycia Therapeutics (LYCA.US), specializing in allergies and autoimmune diseases, will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.

According to Golden Ten Data APP, Lycia Therapeutics, a biotechnology company focused on the treatment of allergies and autoimmune diseases, has expanded the size of its upcoming initial public offering (IPO) in the United States. According to a statement released by the company on Thursday, Lycia will issue 17.64 million shares at a price of $18 per share, aiming to raise $317.5 million. A previous filing showed that the biotech company had originally planned to issue 14.7 million shares at a price range of $16 to $18 per share.